Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products … Read more
Market Cap & Net Worth: Hansoh Pharmaceutical Group Company Limited (HNSPF)
Hansoh Pharmaceutical Group Company Limited (PINK:HNSPF) has a market capitalization of $15.99 Billion ($15.99 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #3763 globally and #2422 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hansoh Pharmaceutical Group Company Limited's stock price $2.69 by its total outstanding shares 5945955423 (5.95 Billion).
Hansoh Pharmaceutical Group Company Limited Market Cap History: 2023 to 2025
Hansoh Pharmaceutical Group Company Limited's market capitalization history from 2023 to 2025. Data shows growth from $8.77 Billion to $15.99 Billion (43.43% CAGR).
Hansoh Pharmaceutical Group Company Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hansoh Pharmaceutical Group Company Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.91x
Hansoh Pharmaceutical Group Company Limited's market cap is 0.91 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.56x
Hansoh Pharmaceutical Group Company Limited's market cap is 2.56 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $8.77 Billion | $10.10 Billion | $3.28 Billion | 0.87x | 2.68x |
| 2024 | $11.18 Billion | $12.26 Billion | $4.37 Billion | 0.91x | 2.56x |
Competitor Companies of HNSPF by Market Capitalization
Companies near Hansoh Pharmaceutical Group Company Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Hansoh Pharmaceutical Group Company Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hansoh Pharmaceutical Group Company Limited Historical Marketcap From 2023 to 2025
Between 2023 and today, Hansoh Pharmaceutical Group Company Limited's market cap moved from $8.77 Billion to $ 15.99 Billion, with a yearly change of 43.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $15.99 Billion | +43.09% |
| 2024 | $11.18 Billion | +27.41% |
| 2023 | $8.77 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hansoh Pharmaceutical Group Company Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.99 Billion USD |
| MoneyControl | $15.99 Billion USD |
| MarketWatch | $15.99 Billion USD |
| marketcap.company | $15.99 Billion USD |
| Reuters | $15.99 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.